Moderna got the FDA to change its mind and review its flu vaccine after some concessions

Core Viewpoint - Moderna's stock experienced a surge following the FDA's decision to review its flu-vaccine candidate, reversing a previous refusal to do so just a week prior [1] Company Summary - The FDA's review of Moderna's flu-vaccine candidate indicates a potential shift in regulatory stance, which could positively impact the company's market position and investor sentiment [1]